Replies to post #408921 on Amarin Corp Plc (AMRN)

[Meowza]

Market gatekeeping by market incumbents isn't the solution. It's the problem.

[Birdbrain Ideas]

I found it significant in HLS's earnings report that it said half of their prescriptions now are written by general practitioners, the very doctors that Pfizer is in charge of promoting Vascepa to. I think Amarin has long said that most prescriptions in the U.S. are written by cardiologists, which is who the company targeted. But if Pfizer began reaching out to general practitioners in the U.S., could Amarin nearly double sales in America? And even if it only gets 50 percent of those sales because the rest goes to generics, wouldn't that be significant additional profits, even if it must pay Pfizer a fee? And wouldn't that also boost Pfizer's interest in buying Amarin?

What is the company waiting for???

Also, wouldn't the announcement of a sales partnership with Pfizer in the U.S. give the stock a nice boost?